Elon Musk’s brain-computer interface company Neuralink is preparing for a major expansion, announcing plans to begin high-volume production of its brain implant devices and transition to a fully automated surgical procedure by 2026. The announcement was made by Musk in a post on the social media platform X, highlighting the company’s long-term vision to scale its neurotechnology and make implantation faster, safer, and more accessible.
Neuralink’s brain implant technology is designed to help people with severe neurological conditions, including spinal cord injuries and paralysis, by enabling direct communication between the brain and external devices. The implant allows users to control digital tools using their thoughts, opening new possibilities for restoring independence and improving quality of life. According to previously shared updates, the first patient implanted with the device has successfully used it to play video games, browse the internet, post on social media, and control a laptop cursor without physical movement.
The company began human trials of its brain-computer interface in 2024 after resolving safety concerns raised by the U.S. Food and Drug Administration. The FDA had initially rejected Neuralink’s application in 2022, citing potential risks, but later approved the trials after additional safeguards were implemented. This marked a significant milestone for the company and the broader neurotechnology industry.
In September, Neuralink revealed that 12 people worldwide with severe paralysis had already received its brain implants. These individuals were reportedly using the technology to control both digital and physical tools purely through thought, demonstrating the real-world potential of brain-computer interfaces. The company has also attracted strong investor interest, securing $650 million in a funding round completed in June, further supporting its research, development, and manufacturing goals.
While Neuralink did not immediately respond to a request for comment, Musk’s statement suggests the company is moving toward large-scale deployment. If successful, high-volume production and fully automated surgical implantation could significantly accelerate adoption of brain implant technology, positioning Neuralink as a leader in the rapidly evolving field of neural interfaces and medical innovation.


Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions
Lenovo Shares Slide as AI-Driven Memory Demand Signals Higher DRAM and NAND Prices
Smartphones are helping filmmakers tell the stories the movie industry overlooks
SK Holdings, KKR Launch $1.3B Renewable Energy Venture in South Korea
TSMC CoWoS Capacity Forecast Raised as Mizuho Sees AI Server CPU Demand Surging Through 2027
Neuralink Expands Brain Implant Trials with 12 Global Patients
Morgan Stanley Raises Tesla Q2 Delivery Forecast on Strong Europe and China Demand
ShareChat Eyes 2027 IPO After Reaching Operational Profitability, Report Says
Super Micro Employees Detained in Taiwan AI Server Export Investigation
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead
Apple Expands iPhone Lineup, Boosts Foldable iPhone Production Plans Through 2027
Chip Stocks Rally as Samsung and SK Hynix’s $1.3 Trillion Investment Plan Boosts AI Optimism
Baige Online Shares Soar 333% in Hong Kong IPO Debut as AI Insurance Demand Lifts Chinese Listings
China vs. NASA: The New Moon Race and What's at Stake by 2030
SoftBank’s LY Corp, Bain Raise Kakaku.com Bid to ¥670 Billion, Intensifying Takeover Battle
EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 



